A Closer Look at Emerging PARP
Inhibitors in the Treatment of Prostate Cancer: Recent Clinical
Trial Data for Improved Clinical and Economic Outcomes
A continuing medical education
activity provided by NAMCP and AAMCN
Clinical Advances in the Treatment of Prostate Cancer: A Closer Look
at the Role of
PARP Inhibitors is a three-part webinar series
This is Part 2 of the series focusing on emerging PARP inhibitors in the treatment of prostate
This activity is an archive from the webinar held February 15, 2021
This activity is valid from March 1, 2021 to March 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
Prostate cancer is the most diagnosed non-cutaneous cancer in men in
the US and remains the second leading cause of cancer deaths among
American men, with an estimated 174,000 new cases diagnosed in 2020.
Prostate cancer deaths are typically the result of
castration-resistant prostate cancer (CRPC), and most patients will
eventually experience disease progression despite castration, with a
median duration of response of 12–24 months. Fortunately for these
patients, novel therapies have changed the treatment paradigm, as
recent data has shown that newer options, including PARP inhibitors,
greatly improves outcomes.
Upon completion of this
activity, participants will be able to:
Examine current unmet clinical needs
in the diagnosis and management of prostate cancer
Analyze recent clinical trial data
on the efficacy and safety of PARP inhibitor therapies in the
management of prostate cancer
Assess the role of emerging PARP
inhibitors in the evolving prostate cancer treatment paradigm
Identify patients who may benefit
from emerging PARP inhibitor therapies in the management of
prostate cancer, including combination therapy
Assess how the potential roles of
biomarkers and barriers to adherence play a role in long-term
treatment decision making for patients with prostate cancer
||Emmanuel S Antonarakis,
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Antonarakis has served as a consultant Amgen, Astellas,
AstraZeneca, Bayer, Clovis Oncology, Dendreon, Lilly,
ESSA, GlaxoSmithKline, Janssen, Medivation, Merck, and
Sanofi. He has recerived grants/research funding from
AstraZeneca, Bristol-Myers Squibb, Celgene, Clovis
Oncology, Dendreon, Genentech, Janssen, Johnson &
Johnson, Merck, Novartis, Sanofi, and Tokai. He is the
co-inventer of a technology licensed to Qiagen. His
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue